Gene biomarkers for prediction of susceptibility of ovarian neoplasms and/or prognosis or malignancy of ovarian cancers

Research output: Contribution to journalArticle

Abstract

The disclosure provides methylome analysis using DNA methylation biomarkers for predicting ovarian cancer prognosis and detecting malignant ovarian cancer. Being independent prognostic factors for patients with current treatment protocols, these DNA methylations are also important biomarkers for treating patients with individualized medicine in future including using chemotherapy, especially the demethylation agents or other epigenetic drugs.
Original languageTraditional Chinese
JournalUS Patent App
Publication statusPublished - Mar 7 2013
Externally publishedYes

Cite this

@article{9247acead19741b8b7e4a730cf23d6a5,
title = "Gene biomarkers for prediction of susceptibility of ovarian neoplasms and/or prognosis or malignancy of ovarian cancers",
abstract = "The disclosure provides methylome analysis using DNA methylation biomarkers for predicting ovarian cancer prognosis and detecting malignant ovarian cancer. Being independent prognostic factors for patients with current treatment protocols, these DNA methylations are also important biomarkers for treating patients with individualized medicine in future including using chemotherapy, especially the demethylation agents or other epigenetic drugs.",
author = "Hung-Cheng Lai and Rui-Lan Huang",
year = "2013",
month = "3",
day = "7",
language = "繁體中文",
journal = "US Patent App",

}

TY - JOUR

T1 - Gene biomarkers for prediction of susceptibility of ovarian neoplasms and/or prognosis or malignancy of ovarian cancers

AU - Lai, Hung-Cheng

AU - Huang, Rui-Lan

PY - 2013/3/7

Y1 - 2013/3/7

N2 - The disclosure provides methylome analysis using DNA methylation biomarkers for predicting ovarian cancer prognosis and detecting malignant ovarian cancer. Being independent prognostic factors for patients with current treatment protocols, these DNA methylations are also important biomarkers for treating patients with individualized medicine in future including using chemotherapy, especially the demethylation agents or other epigenetic drugs.

AB - The disclosure provides methylome analysis using DNA methylation biomarkers for predicting ovarian cancer prognosis and detecting malignant ovarian cancer. Being independent prognostic factors for patients with current treatment protocols, these DNA methylations are also important biomarkers for treating patients with individualized medicine in future including using chemotherapy, especially the demethylation agents or other epigenetic drugs.

UR - https://www.google.com/patents/WO2013033333A1?cl=en

M3 - 文章

JO - US Patent App

JF - US Patent App

ER -